Equities Analysts Set Expectations for BAX Q4 Earnings

Baxter International Inc. (NYSE:BAX) – Equities researchers at Zacks Research cut their Q4 2025 earnings per share estimates for shares of Baxter International in a report issued on Thursday, November 20th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.53 per share for the quarter, down from their prior estimate of $0.70. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s FY2026 earnings at $2.18 EPS and FY2027 earnings at $2.49 EPS.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same quarter in the previous year, the firm earned $0.80 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS.

Several other brokerages also recently commented on BAX. Evercore ISI cut their price target on shares of Baxter International from $31.00 to $24.00 in a report on Thursday, October 30th. Jefferies Financial Group dropped their price objective on Baxter International from $25.00 to $21.00 and set a “hold” rating for the company in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, October 8th. Barclays decreased their target price on Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a research note on Monday, August 4th. Finally, Citigroup cut their price objective on Baxter International from $26.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Baxter International has an average rating of “Reduce” and a consensus target price of $23.70.

Baxter International Price Performance

Shares of NYSE:BAX opened at $18.23 on Monday. The company has a 50 day moving average of $21.17 and a 200 day moving average of $25.49. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30. The stock has a market cap of $9.37 billion, a P/E ratio of -60.75, a P/E/G ratio of 0.73 and a beta of 0.57. Baxter International has a 12 month low of $17.40 and a 12 month high of $37.74.

Baxter International Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, November 28th will be given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, November 28th. Baxter International’s dividend payout ratio (DPR) is presently -6.06%.

Institutional Trading of Baxter International

Several institutional investors have recently added to or reduced their stakes in the business. Zions Bancorporation National Association UT purchased a new position in shares of Baxter International in the first quarter worth about $27,000. CoreFirst Bank & Trust purchased a new position in Baxter International in the 2nd quarter worth approximately $27,000. Imprint Wealth LLC bought a new stake in Baxter International in the third quarter valued at approximately $27,000. Creative Financial Designs Inc. ADV lifted its position in Baxter International by 169.6% in the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 619 shares during the last quarter. Finally, MTM Investment Management LLC purchased a new stake in shares of Baxter International during the second quarter valued at approximately $30,000. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.